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Aims Mitofusin-2 (Mfn2) expression is dysregulated in vascular proliferative disorders and its overexpression attenuates the
proliferation of vascular smooth muscle cells (VSMCs) and neointimal lesion development after balloon angioplasty.
We sought to gain insight into the mechanisms that control Mfn2 expression in VSMCs.
Methods
and results
We cloned and characterized 2 kb of the 5′-flanking region of the human Mfn2 gene. Its TATA-less promoter
contains a CpG island. In keeping with this, 5′-rapid amplification of cDNA ends revealed six transcriptional start
sites (TSSs), of which TSS2 and TSS5 were the most frequently used. The strong CpG island was found to be
non-methylated under conditions characterized by large differences in Mfn2 gene expression. The proximal Mfn2
promoter contains six putative Sp1 motifs. Sp1 binds to the Mfn2 promoter and its overexpression activates the
Mfn2 promoter in VSMCs. Chemical inhibition of Sp1 reduced Mfn2 expression, and Sp1 silencing reduced transcrip-
tional activity of the Mfn2 promoter. In keeping with this view, Sp1 and Mfn2 mRNA levels were down-regulated in
the aorta early after an atherogenic diet in apolipoprotein E-knockout mice or in VSMCs cultured in the presence of
low serum.
Conclusion Sp1 is a key factor in maintaining basal Mfn2 transcription in VSMCs. Given the anti-proliferative actions of Mfn2,
Sp1-induced Mfn2 transcription may represent a mechanism for prevention of VSMC proliferation and neointimal
lesion and development.
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1. Introduction
Vascular proliferative disorders, such as atherosclerosis, restenosis
after balloon angioplasty, and vein-graft disease, are the most
common causes of severe cardiovascular disease. Eventually, arterial
wall thickening, plaque rupture, and occlusion lead to the clinical man-
ifestations of cardiovascular disease (e.g. myocardial infarction and
stroke), the current leading cause of morbidity and mortality in
developed countries.1,2 An important common aetiological factor in
these inflammatory disorders is the development of neointimal
lesions caused by the accumulation of circulating leucocytes, vascular
smooth muscle cells (VSMCs), and non-cellular material (e.g. circulat-
ing lipoproteins, extracellular matrix components). Under normal
conditions, VSMCs residing within the arterial tunica media display a
so-called ‘contractile’ phenotype characterized by low proliferative
and migratory activity and expression of differentiation markers (e.g.
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contractile proteins). However, unlike terminally differentiated
striated muscle cells, VSMCs can revert to a ‘synthetic’ phenotype fea-
turing suppression of differentiation marker gene expression, abun-
dant synthesis of extracellular matrix components, and high
proliferative and migratory activity.3 These pathological processes
are induced by a variety of pathological stimuli, such as atherogenic
stimuli, mechanical stress of the vessel wall, and vessel denudation.2
Thus, VSMC phenotypic switching, hyperproliferation, and migration
into the neointimal layer of the arterial wall are essential components
of neointimal lesion development.
Multiple signalling pathways and molecular networks appear to
control VSMC growth in response to pathological insults.4,5 Recently,
it has been reported that the mitofusin-2 (Mfn2) gene, also named
hyperplasia suppressor gene, encodes a protein whose dysregulation
is involved in vascular proliferative disorders.6 This conclusion is based
on a variety of observations, namely: (i) Mfn2 expression is down-
regulated in hyperproliferative VSMCs from spontaneously hyperten-
sive rat arteries, balloon-injured Wistar Kyoto rat arteries, and apoli-
poprotein E-knockout (ApoE-KO) mouse atherosclerotic arteries;
and (ii) adenoviral-mediated overexpression of Mfn2 suppresses
serum-dependent proliferation of cultured VSMCs and attenuates
balloon injury-induced neointimal VSMC growth and vascular occlu-
sive lesion development in rat carotid arteries. Nevertheless, the func-
tional role of Mfn2 is complex and not limited to the regulation of cell
proliferation. Mfn2 is a mitochondrial outer membrane protein that
primarily participates in mitochondrial fusion,7 activates mitochondrial
metabolism in mammalian cells,8,9 and protects against apoptosis.10
Recently, it has been reported that Mfn2 is enriched at the endoplas-
mic reticulum–mitochondria interface and that Mfn2 in the endoplas-
mic reticulum is required for efficient mitochondrial Ca2+ uptake and
normal ER morphology. This gene is essential in rodents, as mice de-
ficient in Mfn2 die in midgestation, probably because of impaired pla-
cental function caused by a marked reduction in the number of
polyploid giant cells of the placental trophoblast.11 Studies in condi-
tional knockout mice indicate that Mfn2 is required for proper devel-
opment and maintenance of the cerebellum and that the Purkinje cells
require Mfn2 for their extensive dendritic outgrowth and survival. In
humans, Mfn2 mutations cause Charcot–Marie–Tooth type 2A,12
an autosomal dominant neuropathy. In addition, skeletal muscle
Mfn2 is deficient in human obesity and in type 2 diabetes, which sug-
gests that this gene may be involved in the pathophysiology of these
metabolic diseases.8 On the basis of these observations, the present
study was designed to ascertain the mechanisms that regulate Mfn2
transcription by investigating the promoter region of human Mfn2.
2. Methods
2.1 Cloning of human Mfn2 promoter
A human Mfn2 promoter fragment containing positions 21982 to +45
from the transcriptional start site (TSS) was prepared by PCR amplifica-
tion using human genomic DNA templates, and the following primers:
5′-cccgggaggcagaggttgtagtgagttgag-3′ and 5′-gaggcgggaggagggaagtggata-3′ .
The amplified DNA fragment was digested with SacI and SmaI and
cloned into the SacI/SmaI sites of pGL3-promoterless vector (Promega).
2.2 Databases and computer analysis
Potential transcription factor-binding sites were mapped to the Mfn2 pro-
moter using AliBaba (http://www.alibaba2.com) and TESS (http://www.cbil.
upenn.edu/tess/) software. CpG islands were located using the CpGPlot
program (http://www.ebi.ac.uk/emboss/cpgplot/).
2.3 Cell culture
Primary rat aorta VSMCs, C3H10T1/2 cells, and the L6E9 rat skeletal
muscle cell line were used. Primary rat aorta VSMCs were prepared
as described previously.13 Aortas were collected from adult male
Wistar rats euthanized in a CO2 chamber followed by cervical disloca-
tion. Arteries were dissected free from the surrounding tissue and ad-
ventitia and cut into small pieces. Aortic tissue was digested with
collagenase (2 mg/mL, Worthington, OH, USA). VSMCs were grown
in DMEM–F12 (1:1) supplemented with 10% foetal bovine serum
(FBS), 2 mM glutamine, 0.25 mg/mL fungizone, 100 U/mL penicillin,
100 mg/mL streptomycin, and 25 mM Hepes. See details in Supplemen-
tary material online.
2.4 In vivo studies
ApoE-KO mice (C57BL/6J, Charles River, MA, USA) were fed either
control chow or an atherogenic diet for 1 week. Mice were euthanized
and aortas were removed, and immediately snap-frozen. Adult male
Wistar rats were euthanized and tissues removed and frozen. Euthanasia
of the animals was performed in a CO2 chamber followed by cervical dis-
location. Euthanasia was confirmed by checking for lack of response to
limb and tail pinch. All experiments were conducted in accordance with
approved institutional operating protocols (PA-02/10 from Animal
Welfare Ethics Committee at Centro Nacional de Investigaciones Cardi-
ovasculares) and the Directive 2010/63/EU of the European Parliament.
See details in Supplementary material online.
2.5 Rapid amplification of cDNA ends
The TSSs of human Mfn2 in the skeletal muscle were identified using the
FirstChoicew RACE-Ready cDNA (Ambion) following the manufacturer’s
protocol. See details in Supplementary material online.
2.6 Construction of luciferase reporter vectors
The pGL3-promoterless vector was generated by excision of the SV40
promoter by digestion with BglIII/HindIII. The 21982/+45 Mfn2 pro-
moter fragment was cloned into the SacI/SmaI sites of pGL3-promoterless
vector (Promega). The subsequent 5′-deletion constructs were
produced by digestion and religation. See details in Supplementary mater-
ial online.
2.7 Transfection and luciferase assays
VSMCs, C3H10T1/2 cells, or L6E9 cells were seeded at a density of
25 000 cells per well, 24 h before transfection. pGL3 reporter constructs
(250 ng) and 20 ng of Renilla luciferase were transfected using FuGENE
6. At 40 h post-transfection, luciferase and Renilla activity was measured
using the Dual Luciferase Reporter Assay System (Promega). See details
in Supplementary material online.
2.8 Site-directed mutagenesis
A QuikChangew Site-Directed Mutagenesis Kit (Stratagene) was used to
introduce mutations into two putative Inr sites (mutI2: 5′-agtcgcgggg
cagcGgCcgcgtaaggagtaggcg-3′ ; mutI5: 5′-acccgggtcgaggCgGCCGctgaggc
gactggtgacg-3′; mutations are in capitals), following the manufacturer’s
protocol.
2.9 Bisulfite modification of genomic DNA,
PCR, and sequencing
Evaluation of CpG methylation status of the samples was performed by
bisulfite sequencing. Genomic DNA from different sources was modified
with the EzWay DNA Methylation Detection Kit (Koma Biotech) accord-
ing to the manufacturer’s protocol. Modified gDNA was used to
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PCR-amplify a 519 bp region spanning from 2489 to +29 of the Mfn2
gene and sequenced. See further details in Supplementary material online.
2.10 RNA purification and measurement
of mRNA expression
Total RNA was purified using TRIZOL Reagent (GibcoBRL, Invitrogen)
and mRNA expression was determined by real-time PCR, as described
in Supplementary material online.
2.11 Chromatin immunoprecipitation
Chromatin was isolated from rat L6E9 cells and VSMCs. Cells were cross-
linked using a final concentration of 1% formaldehyde for 10 min. The
cross-linking reaction was stopped by the addition of 1.25 M glycine.
Cross-linked cells were washed, collected, and lysed. Nuclei were then
lysed in 50 mM Tris–HCl (pH 8.1), 10 mM EDTA, 1% SDS, and protease
inhibitor cocktail (Roche). Isolated chromatin was then sonicated to an
average fragment size of 400–500 bp. Precleared chromatin was then
immunoprecipitated with antibody against Sp1 (sc-59 X, Santa Cruz
Biotech) and pre-blocked Protein A beads (Sigma). See further details
in Supplementary material online.
2.12 Statistical analysis
Results represent the mean+ SEM of three to five experiments. The
sample size was selected to ensure a statistical power above 80% by
using http://www.stat.uiowa.edu/~rlenth/Power. Statistical differences
were evaluated using Student’s t-test or ANOVA and further post hoc
t-test.
3. Results
3.1 The Mfn2 gene contains a CpG island
that is non-methylated under conditions
characterized by large differences
in Mfn2 expression.
The human Mfn2 gene is located in locus 1p36.22 on chromosome
1. Mfn2 has 19 exons and translation starts in exon 3. In silico analysis
of the 5′-flanking region of human Mfn2 identified putative binding
sites for several transcription factors, including C/EBP and GATA-1,
which may mediate tissue-specific expression of Mfn2, and stress-
response factors such as NFkB and AP-1 (Figure 1A). Oestrogen-
related receptor-a (ERRa)-binding element, which is required for
PGC-1a and PGC-1b stimulation of the Mfn2 promoter is also
shown.14,15 The region near exon 1 is TATA-less, but it contains a
G/C-rich region bearing several potential Sp1-binding motifs
(Figure 1A). The mouse (Figure 1B) and the rat (see Supplementary ma-
terial online, Figure S1) Mfn2 promoters showed a high identity to the
human promoter and also contained putative binding sites for ERR-a,
C/EBP, GATA-1, NFkB, AP-1, and Sp1 transcription factors.
CpG islands are defined as sequences larger than 200 bp with a
proportion of C + G greater than 50% and with a CpG observed/
CpG expected ratio of 0.6 or higher.16 Using the CpGPlot program,
analysis of the human Mfn2 promoter region from 2600 to +600
(relative to the transcription initiation site) revealed a CpG island
that lies between 2266 and +362 (see Supplementary material
online, Figure S2). A CpG island was also detected in the mouse
Figure 1 Nucleotide sequence of the 5′ region of human (A) and mouse (B) Mfn2. +1 indicates the TSS reported in NCBI for human Mfn2 (NM
014874.2) and the homologous site for mouse Mfn2 (NP 573464). The first exon is shaded. Putative transcription-regulatory motifs are in bold and
underlined. Functional ERRa-binding element is shown inside a rectangle.
E. Sorianello et al.40





Mfn2 promoter between 2316 and +225 and in the rat Mfn2 pro-
moter between 2278 and +113 (data not shown). Based on the
CpG ratio, GC content, and length of the CpG-rich region, the
Mfn2 promoter is defined as a high-CpG promoter that represents
a strong CpG island.17
In vertebrates, CpG islands are predominantly non-methylated.18
Non-methylated CpG islands are organized in a characteristic chro-
matin structure that predisposes them towards promoter activity.
As Mfn2 expression has been shown to be ubiquitous, we hypothe-
sized that the Mfn2 promoter CpG island should be in a non-
methylated state in vivo. To this end, we selected cells or tissues
with different expression levels of Mfn2. This included VSMCs or skel-
etal muscle cells (L6E9) before and after differentiation (Figure 2A and
data not shown), rat INS-1 insulinoma, rat H4IIE hepatoma, or rat
FAO hepatoma tumoural cell lines (Figure 2B), or different rat
tissues (Figure 2C). Proliferating VSMCs and L6E9 myoblasts showed
a low Mfn2 expression compared with differentiated cells (Figure 2A
and data not shown), and tissues or rat tumour cells showed variable
expression levels of Mfn2 (Figure 2B and C ). The bisulfite genomic
DNA sequencing technique was used to determine the DNA methy-
lation status of a fragment of the rat Mfn2 promoter region (2262
to 252), containing 15 individual CpG sites (Figure 2D). Sequencing
data evidenced the absence of methylation in any CpG site, regardless
of the cell or tissue analysed. As an example, we show a 41 bp gDNA
fragment (2107 to 267) of the rat Mfn2 promoter region containing
four CpG sites (Figure 2E, first sequence), the same sequence after
Figure 2 Lack of methylation of the 5′-flanking region of human Mfn2. (A) Left: western blot showing the expression of SMa-actin and the con-
stitutive protein ERK2 in differentiated (D) and not differentiated (ND) VSMCs. Right: Mfn2 and acidic ribosomal protein (ARP) mRNA levels
from differentiated and not differentiated VSMCs were measured by real-time PCR (mean+ SEM, *P, 0.01. (B and C) Mfn2 and ARP mRNA
levels from INS-1, H4IIE, and FAO cell lines and from the lung, testis, kidney, and heart from the adult rat, and the aorta from the young and old
rat were measured by real-time PCR (mean+ SEM). (D) Above: bisulfite modified gDNA from differentiated (D) and not differentiated (ND)
VSMCs, L6E9 myoblasts (Mb) and myotubes (Mt), and methylation control (Met) were used as a template for bisulfite sequencing analysis.
Second-round PCR generated a single 312 bp product. N, negative control. *DNA-ladder. Below: 312 bp PCR product and its position in the
Mfn2 promoter (2315 to 24). The grey fragment of 211 bp (2262 to 252) corresponds to the sequencing result. (E) Representative direct se-
quencing results showing four out of the 15 CpG sites studied. Original gDNA (2107 to 267) with the CpG sites indicated in bold, bisulfite modified
gDNA, sequencing result of bisulfite modified unmethylated gDNA (in this case not differentiated VSMCs), and methylation control were shown. ,
SssI methylated cytosine from the CpG motives.
Mfn2 and vascular smooth muscle 41





bisulfite treatment (Figure 2E, second sequence), and the sequencing
result of not differentiated VSMCs (Figure 2E, first electropherogram).
The methylation control showed protection against bisulfite treat-
ment for all cytosine residues analysed (Figure 2E, second electropher-
ogram). Thus, our results indicate the absence of in vivo methylation in
the rat Mfn2 promoter.
3.2 Mfn2 shows multiple TSSs
TATA-less promoters that contain CpG islands usually initiate tran-
scription from multiple weak start sites, which are often distributed
over a region of 100 bp.19 5′-Rapid amplification of cDNA ends
(RACE) was performed to determine whether TSSs other than
those found in the GenBank and localized at +1 and +142. We
used a commercial 5′-RACE-ready kit with an adapter linked only
to mRNA with CAP (from human skeletal muscle) to avoid the amp-
lification of partially degraded mRNA, and nested primers located in
exon 2. Several bands were detected after 5′-RACE (see Supplemen-
tary material online, Figure S3A), which were cloned in the T-A cloning
vector pGEM-T. The sequence of 22 randomly selected clones
revealed two predominant TSSs, one in a narrow window between
27 and 24 (eight clones; TSS2) and another at position +58
(eight clones; TSS5) (see Supplementary material online, Figure S3B).
Additional TSSs were detected at 247 (two clones; TSS1), +37
(one clone; TSS3), +52 (two clones; TSS4), and +124 (one clone;
TSS6) (see Supplementary material online, Figure S3B). Three of
these start sites showed homology with Inr motifs. Transcription in
Inr core promoters can initiate in a single site or in a cluster of mul-
tiple sites in the vicinity of Inr, and not necessarily at the A+1 position,
which seems to be the case of TSS2.20 It is likely that the TSS localized
at +142 according to the GenBank corresponds to an incomplete se-
quence. To examine the role of the most prevalent TSS of human
Mfn2, we cloned the Mfn2 fragment 2229/+348 into a luciferase re-
porter plasmid and performed 5′ deletions. In transiently transfected
10T1/2 cells, the construct 2229/+348-Luc exhibited 200-fold
greater luciferase activity than the promoterless construct, and 5′
deletions up to +84 produced a progressive loss in promoter activity
(70-fold greater activity than the promoterless construct)
(Figure 3A). The construct +123/+348-Luc did not show significant
differences in luciferase activity compared with the promoterless
vector (Figure 3A). Although the +123/+348 Mfn2 fragment main-
tained the TSS6, its loss of promoter activity may be attributable to
the lack of 5′ sequences required for the positioning of basal tran-
scription machinery. Given that TSS2 and TSS5 are the two most
represented TSSs found by RACE analysis, we next examined their
relevance for Mfn2 promoter activity. To this end, the related Inr ele-
ments in TSS2 and TSS5 in 2229/+348-luc were subjected to muta-
genesis by substituting the A+1 and the base at position +3 by G and
C, respectively, which greatly reduces Inr activity both in vitro and in
vivo.21 As commonly found in other CpG island-containing promo-
ters,19 single TSS2 or TSS5 mutations did not modify the activity of
the 2229/+348 promoter in transient transfection assays, but
double mutants showed a 50% reduction in this activity (Figure 3B).
Figure 3 Functional analysis of the proximal human Mfn2 promoter. (A) The region 2229/+348 and deletions at 5′ of human Mfn2 were cloned in
the promoterless pGL3 reporter vector and cotransfected with a Renilla reporter plasmid in 10T1/2 cells. Transcriptional activity was normalized for
the level of Renilla activity and expressed as fold activity of pGL3 promoterless vector. (B) The two main TSSs (TSS2 and TSS5) were mutated in the
construction 2229/+348-Luc as indicated (crossed) and cotransfected with Renilla reporter plasmid in 10T1/2 cells. Transcriptional activity was nor-
malized for the level of Renilla activity and expressed as fold activity of 2229/+348-Luc wild-type (mean+ SEM of three experiments performed in
triplicate; *P, 0.001).
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3.3 Identification of the core promoter
of human Mfn2
Next, we aimed to identify the functionally relevant cis-regulatory ele-
ments in the human Mfn2 promoter. Several fragments spanning
from 21982 to +45 and 254 to +45 (all containing TSS1, TSS2, and
TSS3) were cloned in a luciferase reporter vector and the resulting
constructs were transiently transfected in rat VSMCs or in murine
10T1/2 cells, which show endogenous expression of Mfn2.8,9
The 21982/+45-Luc construct showed 25% stronger promoter
activity than the viral SV40 promoter when transfected in 10T1/2 cells
(data not shown). In VSMCs and 10T1/2 cells, 5′ deletion from 21332
to 2532 caused a marked increase in promoter activity, suggesting
that repressor factors may negatively regulate Mfn2 expression in
these cells by binding to sequenceswithin21332/2532 (Figure 4A). Fur-
thermore, deletion of the region between 2229 and 254 markedly
reduced promoter activity in VSMCs and 10T1/2 cells (Figure 4A). Elim-
ination of this region, while maintaining upstream and downstream
sequences, also caused an 80% reduction in the promoter activity in
10T1/2 cells (Figure 4B). Altogether, our data indicate that the region
2229/254 is critical for maintaining high transcriptional activity of the
human Mfn2 promoter in VSMCs and fibroblasts.
3.4 Regulatory role of Sp1
The 2229/254 region of the Mfn2 promoter is a GC-rich region
with multiple consensus binding sites for Sp1 (Figure 1). It has been
suggested that in promoters contained within CpG islands, Sp1
would direct the basal transcriptional machinery to form a pre-
initiation complex within a loosely defined window.19 To examine
whether Mfn2 promoter activity is affected by the Sp1, we performed
transient transfection experiments with the 21984/+45-pGL3 con-
struct and expression vectors encoding Sp1. In 10T1/2 cells, Sp1
induced a three-fold increase in luciferase activity (Figure 5A). In
VSMCs, Sp1 also enhanced the promoter activity (4.5-fold)
(Figure 5A).
In order to assess Sp1 binding to the Mfn2 promoter, chromatin
immunoprecipitation (ChIP) assays were performed. Endogenous
chromatin of primary rat VSMCs or L6E9 muscle cell cultures
was immunoprecipitated with or without anti-Sp1 antibodies. The
precipitated genomic DNA was then analysed by PCR using the
primers encompassing the Sp1-binding site in the Mfn2 promoter.
Chromatin fragments containing the Sp1 DNA-binding site from
the Mfn2 promoter region were specifically immunoprecipitated
by anti-Sp1 antibody (Figure 5B) showing specific amplification
band for both VSMCs and L6E9 cells. No chromatin fragments
were immunoprecipitated in the absence of antibody (Figure 5B).
Binding of Sp1 to the promoter region of Mfn2 was specific, as
no chromatin fragments in the coding region of Mfn2 (exon 2)
or in the intergenic region 10 kb upstream of the Mfn2 TSS
were immunoprecipitated with the anti-Sp1 antibody (Figure 5B).
Thus, endogenous Sp1 binds to Mfn2 promoter in primary
VSMCs and L6E9 cells.
Figure 4 Functional analysis of human Mfn2 promoter. (A) 21982/+45-Luc and 5′ deletions, as indicated on the left panel, were cotransfected with
a Renilla reporter plasmid in 10T1/2 (open square) and VSMCs (filled square). Cells were harvested 40 h after transfection and luciferase activity was
determined. Transcriptional activity was normalized by Renilla and expressed as fold activity of pGL3 promoterless vector. (B) The region 2229/254
was deleted in the construction 2532/+45-Luc by restriction digestion. Each construct was cotransfected with a Renilla reporter plasmid in 10T1/2
cells. Transcriptional activity was normalized by Renilla and expressed as fold activity of 2532/+45-Luc wild-type vector (mean+ SEM of three
experiments performed in triplicate).
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Considering that Sp1 binds to Mfn2 promoter and increases Mfn2
promoter activity in cell cultures, we wanted to assess whether this
effect/phenotype was also present in a more physiological in vivo
model. Consistentwith previous studies showing reducedMfn2 expres-
sion in arteries from apolipoprotein E-null mice (ApoE-KO) subjected
to a high-fat diet,6 we found a marked reduction in Sp1 mRNA levels
in the aorta from Apo E-KO mice fed an atherogenic diet for 1 week
(50% decrease vs. control diet) (Figure 5C, left panel). Under these con-
ditions,Mfn2mRNA levels also underwent a significant reduction (60%
decrease) (Figure 5C, right panel). The effects of an atherogenic diet
were transient and no effects on Sp1 or Mfn2 gene expression were
detected in the aorta after more prolonged treatment (2 months)
(data not shown). These data suggest that down-regulation of Sp1 at
the onset of atherosclerosis contributes to reducedMfn2 transcription
in aortic tissue. A similar co-regulation of Sp1 and Mfn2 was detected
upon culturing VSMCs in normal (10% FBS) or low serum (0.2%
during 48 h) conditions. Total RNA was obtained and real-time PCR
assays were performed. Sp1 gene expression was lower in VSMCs cul-
tured in 0.2% FBS than in the normal serum condition (Figure 5D, left
panel). Accordingly, Mfn2 mRNA levels were also down-regulated in
this situation (Figure 5D, right panel).
Searching for the in vivo effects of Sp1 depletion on Mfn2 protein
expression, a shRNA approach was used. In order to knock down
Sp1 expression, we infected VSMCs and L6E9 cultures with lentivirus
encoding specific Sp1 shRNA (shSp1) or scramble control sequences
(C). Western blot analysis revealed an almost total depletion of Sp1
protein in shSp1 transduced VSMCs and an 85% down-regulation in
shSp1 transduced L6E9 cells (Figure 6A and B).
In order to evaluate the impact of Sp1 loss-of-function on Mfn2
promoter activity, control and Sp1-depleted cells were transfected
with the 2532/+45-pGL3 or 2229/254-pGL3 and promoter activ-
ity was tested. As expected, the luciferase assay showed a significant
decrease in promoter activity in Sp1 knock-down cells compared with
controls (Figure 6C). The construct containing the 21984/+45 pro-
moter region showed the same result (data not shown). Thus,
these data confirms the essential role of Sp1 in Mfn2 promoter
activation.
Sp1 consensus binding sites are targets for specific inhibitors. Thus,
next we examined the role of Sp1 in the control of Mfn2 gene expres-
sion, by using WP631, a specific inhibitor of Sp1.22,23 For this purpose,
L6E9 cells transfected with 2532/+45-pGL3 or 2229/254-pGL3
constructs were incubated in the presence of 300 nM WP631
during 24 h. As shown in Figure 6D, WP631 caused a 90% inhibition
in luciferase activity for both constructs. In order to further assay
WP631 action, we incubated primary rat VSMCs with the compound
and analysed Mfn2 transcript expression. Incubation of VSMCs with
Figure 5 Mfn2 promoter is regulated by Sp1 transcription factor. (A) The 21982/+45-Luc vector was cotransfected with GFP and Sp1 expression
vectors in 10T1/2 cells (open square) or was cotransfected with Renilla in VSMCs (filled square). Transcriptional activity was normalized and
expressed as fold activation of 21982/+45-Luc (basal) (mean+ SEM of three experiments performed in triplicate; *P, 0.01). (B) ChIP of endogen-
ous Sp1 in the Mfn2 promoter. In vivo cross-linked chromatin from rat VSMCs or L6E9 cells was immunoprecipitated with anti-Sp1 or without anti-
body, followed by PCR amplification using specific primers for the Mfn2 promoter, the exon 2, and an intergenic region 10 kb upstream of the Mfn2
TSS. (C) ApoE-KO mice were fed during 1 week with control chow (open square) or atherogenic diet (filled square). Sp1 and Mfn2 mRNA from the
aorta were measured by real-time PCR and expressed relative to Cyp mRNA levels (mean+ SEM, four pools of each diet; *P, 0.05). (D) Sp1 and
Mfn2 mRNA expression from rat VSMCs cultured in 10 or 0.2% FBS during 48 h was determined by real-time PCR (mean+ SEM of three experi-
ments performed in triplicate; *P, 0.05).
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different nanomolar concentrations of WP631 for 24 h caused a sig-
nificant reduction in Mfn2 mRNA levels (Figure 6E). In addition, incu-
bation with WP631 markedly reduced Mfn2 mRNA levels in MCF-7/
VP cells (data not shown), in agreement with a direct effect of WP631
on Sp1-regulated Mfn2 transcription.
4. Discussion
In the present study, we have both identified and characterized the
promoter regions of human, mouse, and rat Mfn2 genes. These pro-
moters contain a region of 500 bp which satisfies the criteria for the
presence of a strong CpG island.16,17 Under in vivo conditions, no
evidence for methylation has been found, which is in agreement
with data, indicating that strong CpG island-containing promoters
are not methylated.17,24 We have also shown that the human Mfn2
promoter is TATA-less and that the 2229/+123 region, which con-
tains six putative binding sites for the transcription factor Sp1, is es-
sential for normal transcriptional activity. In keeping with the above,
human Mfn2 shows six TSSs. The functional relevance of Sp1 tran-
scription factor in the control of Mfn2 expression is suggested by
the following findings: (i) Sp1 overexpression enhances the transcrip-
tional activity of the Mfn2 promoter, (ii) Sp1 ablation down-regulates
Mfn2 promoter activity in VSMCs and L6E9 cells; (iii) the stimulatory
effect of Sp1 onMfn2 promoter activity is abolished pharmacologically
Figure 6 Mfn2 promoter activity is abolished in response to Sp1 deficiency. (A) Western blot of total extracts obtained from rat VSMCs and L6E9
cells transduced with lentiviral vectors encoding Sp1 shRNA (shSp1) or scramble control sequences (C). Sp1 and tubulin proteins were detected using
specific antibodies, n ¼ 3–5. (B) Relative protein expression of Sp1 from rat VSMCs and L6E9 cultures transduced with lentiviral vectors encoding Sp1
shRNA (shSp1) or scramble control sequences (C) (mean+ SEM of three to five experiments; *P, 0.05). (C) The 2532/+45-pGL3 or
2229/254-pGL3 vectors were cotransfected with Renilla expression vector in L6E9 cells transduced with lentiviral vectors encoding Sp1 shRNA
(shSp1) or control plasmid (C). Transcriptional activity was expressed as fold change of control (mean+ SEM of three experiments performed in
triplicate; *P, 0.01). (D) The 2532/+45-pGL3 or 2229/254-pGL3 vectors were cotransfected with a Renilla expression vector in L6E9 cells.
Four hours after transfection, cells were incubated with 300 nM WP631 (WP631) or PBS (Basal) during 24 h. Transcriptional activity was expressed
as fold change of control (mean+ SEM of three experiments performed in triplicate; *P, 0.01). (E) VSMCs were treated with various concentrations
of WP631 for 24 h. Thereafter, total RNA was extracted, and Mfn2 and Cyclophilin A mRNA levels were analysed by real-time PCR (mean+ SEM of
five experiments; *P, 0.05).
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by using the specific Sp1 inhibitor WP631, (iv) Sp1 binds in vivo to the
Mfn2 promoter; and (v) ApoE-KO mice subjected to an atherogenic
diet undergo a concomitant reduction in Mfn2 and Sp1 mRNA
levels in the aorta. Altogether, our data demonstrate that the
human Mfn2 promoter belongs to the class of CpG dispersed promo-
ters,25 in which methylation is prevented under in vivo conditions and
in which transcription is driven and regulated by Sp1.
The Mfn2 promoter represents a model to understand the ele-
ments responsible for the core promoter function of promoters
located in CpG islands. This aspect is particularly relevant since the
specific mechanisms that control the activity of promoters located
in CpG islands are not well understood19 in spite of the fact that
almost 60% of the promoter regions of human genes are located
within these islands.26 Using 5′-RACE, we found that transcription
of Mfn2 in the human skeletal muscle can be initiated in at least six
TSSs, which show homology with Inr elements, a common feature
of promoters in CpG islands.19 The two main transcriptional start
points identified by sequencing of 5′-RACE products, TSS2 and
TSS5, were mutated to examine their functional importance. Individu-
ally, mutation did not change the strength of the promoter, although
the double mutant reduced promoter activity by 50%. These results
indicate that the human Mfn2 gene constitutes a redundant system
capable of maintaining high promoter activity even after mutation of
the most frequently used individual TSSs. In addition, our data demon-
strate the presence of 5′ heterogeneity of the Mfn2 transcripts of
human origin, which may have an impact on the biological activities
of the products of this gene.
DNA methylation involves the addition of methyl groups to cyto-
sine located 5′ to guanine in CpG nucleotide pairs, and methyl-CpG
is now recognized as a gene-silencing signal.27,28 In healthy adult
tissue, strong CpG islands are usually unmethylated. Thus, de novo
methylation depends on the local CpG density, making it more
likely for weak CpG islands.17 In agreement with these observations,
we found no methylation of the Mfn2 promoter in cultured cells from
tumour origin, adult rat tissues or rat VSMCs, or skeletal muscle cells
before and after differentiation. However, methylation of human Mfn2
is undertaken in vitro by HpaII or SssI methylases (data not shown),
which suggests that under in vivo conditions, different factors may
cause steric hindrance and prevent methylation. The fact that we
did not found any tissue or cell type in which Mfn2 expression was
completely absent points to the essentiality of Mfn2 function in
cells. Thus, the demethylated CpG island status and the concomitant
open chromatin structure of the promoter seem to be necessary to
guarantee at least a minimal Mfn2 promoter activity/Mfn2 expression.
Whether other pathological conditions cause methylation of the Mfn2
promoter remains to be elucidated.
We have identified cis-regulatory elements and transcription factors
involved in the regulation of human Mfn2 promoter activity. In the cell
types tested (rat VSMCs, and murine 10T1/2 fibroblasts), deletion of
the 21332/2532 region enhanced promoter activity, thereby provid-
ing evidence for the operation of repressor factors. In addition, dele-
tion of the 2229/254 region suppressed promoter activity, thereby
providing evidence that this is a critical region of the core Mfn2 pro-
moter. Consistent with the observation that the presence of several
putative Sp1-binding sites is a common feature of CpG islands,19
computer-assisted sequence analysis of the human Mfn2 promoter
revealed six potential consensus sequences for the Sp1 family of tran-
scription factors in the 2229/254 region. Importantly, Sp1 over-
expression increased Mfn2 promoter transcription in fibroblasts and
VSMCs, and this activation was abolished by in vitro promoter methy-
lation. In addition, Sp1 binding to the Mfn2 promoter was confirmed
for VSMCs and L6E9 cells, suggesting that its function as a transcrip-
tional activator on Mfn2 is not restricted to a specific cell type.
Further in vivo evidence demonstrated that in aortas from ApoE-KO
mice subjected to a high-fat diet, Sp1 as well as Mfn2 expression were
decreased. The effects of an atherogenic diet were transient and no
effects on Sp1 or Mfn2 gene expression were detected in the aorta
after more prolonged treatment (2 months). The transient repression
of Mfn2 detected early after the implementation of an atherogenic
diet is similar to the transient repression of Mfn2 detected in
carotid arteries after a mechanical injury induced by angioplasty.6 In
keeping with the observations in the aorta, VSMCs showed a parallel
reduction in Sp1 and Mfn2 mRNA expression levels when grown in
low-serum conditions. In addition, Sp1 inhibition caused Mfn2 gene
repression in VSMCs. Therefore, our studies provide solid evidence
that Sp1 binds to Mfn2 promoter and regulates Mfn2 expression in
several in vivo systems.
In conclusion, Sp1 binds to the Mfn2 promoter in different cells
types, which includes VSMCs and skeletal muscle cells, and transacti-
vates the basal machinery of Mfn2. Sp1 has been reported to inhibit
VSMC proliferation by induction of p27 and by repression of p21 ex-
pression and cyclin D1–Cdk4–p21 complex formation.29,30 In this
study, we provide evidence for a stimulatory role of Sp1 on Mfn2 ex-
pression in VSMCs. Based on the antiproliferative action of Mfn2 in
VSMCs, our data reveal a new mechanism by which Sp1 may
prevent the development of vascular proliferative disease.
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